Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

INTRODUCTION: Drotrecogin alfa (activated; recombinant activated protein C) was shown to reduce 28-day all-cause mortality in patients with severe sepsis and to have an acceptable safety profile in 1690 patients studied in the F1K-MC-EVAD (PROWESS) trial. We analyzed all available data on the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernard, Gordon R, Macias, William L, Joyce, David E, Williams, Mark D, Bailey, Joan, Vincent, Jean-Louis
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC270661/
https://www.ncbi.nlm.nih.gov/pubmed/12720562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC270661/
https://www.ncbi.nlm.nih.gov/pubmed/12720562

Ejemplares similares